Chapter 6: Individual Variation in Drug Responses

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine you prescribe the exact textbook dose of a standard seizure medication.

You check the patient's weight, their renal function is pristine,

everything looks perfect.

But because you didn't check for one specific seemingly invisible genetic allele, your patient develops a fatal skin condition within days.

That is the terrifying reality of the cookie cutter approach to medicine.

It really is, and it's a reality that advanced practice nurses and PAs face every single day.

The textbook dosage is kind of an illusion.

It is a statistical average that doesn't actually exist in the exam room.

Welcome to a special Last Minute Lecture deep dive.

If you are an advanced practice nursing or a physician assistant student gearing up for exams or, you know, stepping into clinical practice, you are exactly where you need to be.

Absolutely.

Today, our mission is to completely master Chapter 6 of Lanny's Pharmacotherapeutics, which is individual variation in drug responses.

And we're not here to memorize lists, right?

We're here for a personalized tutoring session to understand the cellular and physiological why behind drug variations.

Because prescribing is never static.

I mean, you can memorize clinical guidelines until you're blue in the face, but those guidelines only keep patients safe when we adjust them for the unique physiological, genetic, and social variables of a specific individual sitting right in front of us.

Right, exactly.

So, before we even get to the DNA or the complex pathophysiology, we have to look at the physical vessel receiving the medication.

Let's start with body size and composition.

Okay, yeah.

I mean, we all know a pediatric dose is smaller than an adult dose, but the mechanics of calculating that are where, well, where mistakes happen.

Absolutely.

The fundamental rule of pharmacology is that the intensity of a drug's response is dictated by its concentration at its site of action.

So if you give the exact same milligrams to a very small person and a very large person… It's going to be way more concentrated in the smaller person.

Exactly.

That drug achieves a much higher concentration in the smaller patient system.

You risk severe toxicity in the smaller patient and total therapeutic failure in the large one.

Okay, let's unpack this.

It's like applying fertilizer to a lawn.

You can't just base the amount of fertilizer on the sheer weight of the dirt in the yard.

Right.

You need to know the square footage, like the actual surface area you're trying to cover, to get an even distribution.

That is a brilliant way to conceptualize it, and it explains exactly why dosing by body surface area, or BSA, is vastly superior to dosing by weight alone.

Weight is a blunt instrument.

BSA doesn't just account for how heavy the patient is, it provides a much more accurate proxy for their relative amount of body adiposity or body fat.

Because fat alters distribution, right?

If you give a highly lipophilic drug to someone with a high percentage of body fat, it's going to sequester in that tissue.

Precisely.

It changes the volume of distribution.

Lipophilic drug gets absorbed into the adipose tissue,

meaning less of it is immediately available in the bloodstream to actually hit the target receptor.

Oh, I see.

Conversely, a hydrophilic drug won't distribute into fat.

So in a patient with high adiposity, more of the drug stays in the blood, potentially driving up the serum concentration to dangerous levels.

Using BSA just gives you a much tighter control over that response.

Which is incredibly critical in pediatrics, but age itself is a massive variable independent of size.

We have the two extremes, right?

Infants and older adults.

Right.

And they are highly sensitive to drugs for completely different physiological reasons.

In infants, this heightened sensitivity is all about organ immaturity.

Like the blood -brain barrier.

Exactly.

Their blood -brain barrier isn't fully developed, making them exquisitely sensitive to CNS drugs.

Their hepatic enzymes haven't fully come online yet, and their renal excretion is, well, it's severely limited.

While older adults are facing the exact opposite problem, it's not immaturity, it's a gradual decline.

Right.

You're dealing with a loss of functional nephrons, which reduces renal clearance, decreased hepatic blood flow, slowing down metabolism, and altered body composition.

Like less lean muscle mass and more body fat.

And usually a ton of other medications, too.

Exactly.

Plus, it's compounded by the presence of multiple comorbidities and polypharmacy.

This really sets the foundation for so much of your clinical reasoning in later chapters.

It makes a lot of sense.

But let's look at what happens when those major systems actively start to fail.

I want to talk about pathophysiology.

As clinicians, we know the liver handles metabolism and the kidneys handle excretion.

But how drastically does this change the day -to -day prescribing math?

Oh, it changes everything.

Let's look at renal decline.

If kidney function drops, usually measured by a declining glomerular filtration rate, or GFR drugs simply cannot leave the body, the excretion rate just plummets.

So if a clinician doesn't proactively lower the dosage or extend the dosing interval, the drug accumulates in the blood and quickly reaches toxic levels.

And the liver presents a similar trap, just through a different mechanism.

Exactly.

The liver is packed with CYP450 enzymes that break down medications.

If a patient develops cirrhosis or hepatitis, the liver's ability to metabolize drugs basically stalls out.

Yeah, the active drug stays active much longer.

Again, if a drug is primarily processed by that affected organ, the dosage must be drastically reduced or you need to select a different medication entirely.

So the body's filters are clogged and you have to pour less water in, I follow that.

But the text also dives into acid -base imbalance and this concept of pH partitioning.

This usually trips students up.

Why does the blood's pH matter to a pill sitting in the stomach?

This is where understanding the cellular mechanics is crucial.

Cell membranes are lipid bilayers.

For a drug to be absorbed, it usually has to cross those membranes.

But charged molecules, ions, cannot easily cross a lipid bilayer.

They just bounce right off.

Exactly.

Because of pH partitioning, a drug will accumulate on the side of a membrane where the pH most favors its ionization.

Acidic drugs ionize, meaning they gain that electrical charge, in an alkaline environment.

And basic drugs ionize in an acidic environment.

So if a drug gets ionized, it gets stuck there?

We call it ion trapping.

If you have an acidic drug in the relatively alkaline blood,

it ionizes and gets trapped in the plasma, unable to cross into the tissues.

Oh wow.

Yeah.

If a patient's acid -base status shifts, like due to respiratory failure or metabolic acidosis, it can completely alter where a drug gets trapped, drastically changing its distribution and excretion.

Okay, what about altered electrolyte status?

Because thinking about real patients,

electrolytes fluctuate all the time.

A patient's potassium or sodium levels are constantly shifting slightly.

Does every minor potassium shift ruin every medication?

What's fascinating here is that, broadly speaking,

clinically significant electrolyte drug disruptions are actually quite rare.

The body is remarkably good at buffering normal fluctuations.

When it fails?

When it fails, it is incredibly high stakes.

As a prescriber, the absolute must -know example is digoxin in the presence of hypokalemia, or in a low potassium.

Walk me through the mechanics of that.

Why potassium specifically?

Well, digoxin and potassium actually compete for the exact same binding sites on the sodium -potassium ATPase pump in the heart muscle.

If potassium levels drop too low, there's no competition.

Oh, so the drug just takes over.

Exactly.

Digoxin suddenly has free rein to bind to way more receptors than intended.

This drastically increases the drug's effect and can quickly induce fetal dysrhythmias.

That's why strict serum potassium monitoring is completely non -negotiable for any patient on digoxin.

It's all about receptor competition.

That's fascinating.

And lithium has a similar high -stakes relationship with sodium, right?

It does.

The kidneys process lithium and sodium in very similar ways.

If a patient's sodium levels fall, maybe they are on a diuretic or heavily sweating the kidney's attempt to conserve sodium.

Right, the body tries to hold on to it.

But in doing so, they also hold on to the lithium.

This leads to lithium accumulation and severe toxicity.

On the flip side, if sodium levels are high, the body excretes more of it, taking the lithium right along with it and diminishing the drug's therapeutic effect.

Man, it's such a delicate balance.

So we've covered how the organs, the pH, and the electrolytes handle drugs.

Now let's talk about adaptation.

How do the receptors and the mind adapt to these chemicals over time?

I want to break down tolerance.

Tolerance is a decreased responsiveness to a drug as a result of repeated administration.

Basically the patient needs higher doses to achieve the original effect.

Clinically, we have to distinguish between three distinct mechanisms.

Okay, let's start with pharmacodynamic tolerance.

This one makes sense to me.

It's what happens with opioids like morphine.

It's an adaptive process where the receptors themselves physically down -regulate in response to being constantly bombarded by the drug.

So the minimum effective concentration, the MEC, gets pushed higher.

Exactly.

The cells demand more drug just to hit the new baseline threshold for an effect.

But the second type, metabolic tolerance, is entirely different.

Rick, I've seen patients whose bodies just seem to chew through a drug faster without the receptors changing at all.

Is that what metabolic tolerance is?

You nailed it.

This tolerance results from accelerated drug metabolism.

Certain drugs, like barbiturates,

actually induce the synthesis of hepatic drug metabolizing enzymes.

The liver literally builds more CYP machinery to break the drug down.

Wow.

And in metabolic tolerance, the MEC doesn't change.

The receptors are just as sensitive as before.

You just need a higher dose because the liver is destroying the drug before it can reach the target.

Okay, so pharmacodynamic is the receptors getting numb.

Metabolic is the liver working in overdrive.

What about tachyphalaxis?

Tachyphalaxis is a rapid reduction in responsiveness brought on by repeated dosing over a very short time, like hours, not days or weeks.

It's like the drug just runs out of fuel to do its job.

That's a perfect analogy.

Yeah.

Transdermal nitroglycerin patches are the classic example.

If you leave a nitro patch on a patient around the clock, it completely loses its effect in less than 24 hours.

Because it depletes a specific cellular cofactor, right?

Exactly.

Nitroglycerin requires intact sulfhydryl groups in the cell to function.

Continuous exposure depletes those groups.

That's why an intermittent schedule is mandatory.

You prescribe a patch -off period, usually overnight, to let the cofactors replenish.

And then the next morning, the drug works perfectly again.

That is such a vital clinical pearl for a PA or NP to remember.

Now shifting gears from the physical receptors to the mind, the placebo effect, I feel like gets a terrible rap.

It means the provider thinks the patient is faking it.

That is a dangerous misconception we really need to clear up immediately.

A placebo itself, the sugar pill, has no intrinsic pharmacologic activity.

The placebo effect is the component of a drug response caused by psychological factors.

Right.

But, and this is vital, a psychological trigger causes a real, measurable, biochemical and physiologic response in the body.

So their pain relief is real.

Absolutely real.

Right.

When a patient expects pain relief, their brain can release endogenous opioids.

When anxiety drops, sympathetic nervous system tone drops, which lowers heart rate and blood pressure.

That's incredible.

Yeah, the presence of a placebo response does not imply that the original pathology was imaginary.

It works both ways.

If a patient is convinced a drug will cause nausea, that negative expectation can literally trigger the vomiting center in the brain.

So fostering an optimistic, transparent and realistic attitude with your patient isn't just good bedside manner, it is an active therapeutic tool.

It's a fundamental part of pharmacology.

Okay, so the mind's expectation is a massive variable,

but physically getting the pill from the stomach into the bloodstream is another entirely.

Let's talk about the gut and variability in absorption.

The key metric here is bioavailability.

This refers to the fraction of an administered dose of unchanged drug that actually reaches the systemic circulation.

Different formulations of the exact same active ingredient can have different bioavailabilities.

Because of how they're made.

Factors like the tablet's disintegration rate, or if it has an enteric coating designed to survive stomach acid,

alter how much drug actually gets absorbed.

As a prescriber, how much do you have to stress over this?

Like if a patient switches from a brand name drug to a generic equivalent at the pharmacy, does it matter?

If we connect this to the bigger picture, usually no.

With most oral preparations, variations in bioavailability are so small they lack clinical significance.

However, this changes entirely if you are prescribing a drug with a narrow therapeutic range.

Because there's almost zero margin for error.

Exactly.

With a narrow therapeutic index, the line between an ineffective dose and a toxic dose is incredibly thin.

A tiny decline in bioavailability causes therapeutic failure, and a tiny increase causes toxicity.

In those cases, like with certain anti -seizure medications or immunosuppressants, variations matter a great deal.

And it's not just the pills manufacturing, right?

The patient's own body alters the absorption.

Gastric emptying time, transit time through the intestine.

Let's elevate this.

Let's say you prescribe an anticholinergic drug for an overactive bladder.

That drug inherently slows down gastrointestinal motility.

That's a great clinical scenario.

If they're also taking a second medication with a narrow therapeutic index that gets absorbed in the intestine,

you've just inadvertently increased the time that second drug sits in the gut.

Which means it keeps absorbing.

Exactly.

Prolonged transit time enhances absorption, which could potentially drive the serum levels of that second drug into toxicity.

So you treated the bladder but accidentally caused an overdose of a completely different medication.

Which is why polypharmacy requires looking at the whole board, not just individual pieces.

You also have to consider things like diarrhea,

which accelerates transport and drastically reduces absorption time, potentially leading to treatment failure.

We've talked about the physical structure and the gut,

but all of this is dictated by the underlying blueprint.

We need to talk about the cellular code,

so genetics, sex, and ancestry.

This is an area of rapid evolution.

For decades, the medical community had a massive blind spot.

Most research on drugs approved before 1997 was conducted almost exclusively on cisgender men of European ancestry.

Which is wild to think about considering you're treating the entire spectrum of humanity.

It was a profound failure in data collection.

But the FDA eventually pushed back and in 2020 published strict guidelines to enforce diversity in clinical trials, ensuring the inclusion of different sexes, races, ages, and even specific comorbidities.

Because biological sex creates massive variations in drug response.

A drug might be highly effective in men, but completely fail in women, or vice versa.

For example, Degoxin, which we discussed earlier regarding potassium, has actually been shown to increase mortality in women when used for heart failure, while having no effect on mortality in men.

That is a staggering difference to just discover after the fact.

It is.

We also know women metabolize alcohol more slowly due to differences in gastric enzymes.

Certain opioid analgesics, like Nalbufene, are much more effective in women.

Really?

Yeah, and here is a critical safety alert for your clinical practice.

Quinidine, an antiarrhythmic, causes much greater QT interval prolongation in women than in men, significantly increasing the risk of fatal cardiac events.

And the text makes a crucial point about prescribing for transgender patients here too.

Yes.

While research is still catching up, early studies show that transgender women receiving gender -affirming hormone therapy also exhibit a longer QT interval, mirroring the physiology of cisgender women.

Oh, wow.

This means you must take extra care when prescribing QT -prolonging drugs to transgender women, remaining highly alert, because historical data based purely on sex assigned at birth will not accurately predict their response.

It's incredible how much a single allele dictates a drug's success.

Here's where it gets really interesting.

This brings us to Ancestry and how specific genetic variations dictate life or death.

It's quite literal.

Pharmacogenomics has identified several ancestry -linked genetic differences.

For instance, some individuals of Asian heritage carry the HLAB -STAR -1502 allele.

If you prescribe them Cardamazepine, common seizure medication, their immune system recognizes the drug complex as a foreign antigen.

And that triggers a reaction.

A massive one.

It triggers an inflammatory cascade, resulting in fatal skin conditions like Stevens -Johnson syndrome and toxic epidermal necrolysis.

So the clinical protocol is mandatory genetic screening.

Yes.

The FDA highly recommends genotyping patients of Asian ancestry before prescribing Cardamazepine.

Similarly, genetic screening for the HLAB -STAR -5701 allele is recommended before prescribing the HIV medication abacavir, because carrying that allele puts the patient at high risk for fatal multi -organ hypersensitivity.

And there are specific guidelines regarding antiretroviral therapy and African ancestry,

That's right.

Research showed that women with African ancestry who started antiretroviral therapy using integrase strand transfer inhibitors, or IST inhibitors, were significantly more likely to gain greater than 10 % of their pretreatment body weight compared to other populations.

That's a huge metabolic shift.

Exactly.

Because of this, clinical guidelines suggest considering non -NST therapy for these patients to mitigate that severe metabolic side effect.

Which leads us perfectly into the Bdil controversy.

The text uses this as a case study for race -based drug approval.

Bdil is a fixed -dose combination of two vasodilators for heart failure.

In 2005, it became the first drug approved by the FDA specifically for treatment of a single racial group.

This was based on the AFT trial, which showed a remarkable 43 % reduction in one -year mortality for self -described Black patients.

A 43 % reduction in mortality is massive.

But clinically, prescribing purely based on self -identified race feels completely imprecise, right?

Because race is a social construct, not a biological or genetic one.

So what was the actual genetic mechanism they missed by not studying everyone?

You've hit the exact core of the controversy.

The trial explicitly excluded populations other than self -described Black patients.

Because of that exclusion, there is absolutely no evidence that Bdil wouldn't work just as well for patients of other races who share the underlying unidentified genetic variations that made the drug so effective.

They used a social category as a sloppy proxy for a genetic marker.

Precisely.

And that's why the ongoing HFF trial in Denmark is currently investigating its efficacy in other populations, with results expected soon.

It highlights the profound danger of a one -size -fits -all approach based on race, without demanding to understand the actual underlying pharmacogenomics.

It's a perfect example of why you have to look deeper.

But even if you crack the genetic code perfectly and calculate the exact renal clearance, that prescription is completely useless if the patient never fills it.

Let's zoom out to the environment the patient actually lives in.

We need to talk about comorbidities and the social determinants of health.

Patients rarely walk into a clinic with just one isolated medical issue.

Comorbidities lead to polypharmacy, and polypharmacy leads to adverse interactions.

A classic case -based application is a patient with both hypertension and asthma.

Right.

You prescribe a non -selective beta blocker to control their blood pressure.

But because it's non -selective, it also blocks the beta -2 receptors in the lungs.

Exactly.

And in a patient with asthma, blocking those beta -2 receptors causes severe, potentially life -threatening bronchoconstriction.

You successfully treated the blood pressure, but you put them in respiratory distress.

You must treat the whole patient.

You also have to consider structural changes, like bariatric surgery.

If a patient has a gastric bypass, they lose the massive absorptive surface area, the duodenum.

That fundamentally changes the pharmacokinetics of how oral drugs are absorbed into their system.

And then there are the non -medical factors.

The text lays this out brilliantly in Table 6 .1, breaking down the social determinants of health into five domains.

But instead of just checking boxes, let's look at how this plays out in a real clinical scenario.

Imagine treating a child with severe, uncontrolled asthma.

It's the perfect example.

You might prescribe the most genetically targeted, perfectly dosed inhaled corticosteroid.

But let's look at the domains.

First, economic stability.

If the family lives in poverty, they cannot afford a $300 brand name inhaler.

The prescription just goes unfilled.

So as a prescriber, you have to actively seek out cheaper equivalents or connect them with patient assistance programs.

Then there's education access.

If the parents lack health literacy,

all the complex physiological explanations in the world won't help them administer the inhaler correctly.

You have to use lay terms, demonstrate with a spacer, and provide visual translated materials if English isn't their primary language.

What about healthcare access?

Let's say they don't have a car to get to the pediatric pulmonologist across town.

Then you adapt your care plan.

You partner with local health departments or community clinics, or you help them set up a mail order pharmacy service so the lack of transportation doesn't sever their access to the drug.

And neighborhood and built environment.

This is huge for asthma.

It's everything.

You have to ask where they live.

Do they live in an apartment right next to a major highway breathing in diesel particulate?

Are there throw rugs trapping dust mites in the child's bedroom?

You have to educate the family about modifying their indoor spaces because the drug can't outcompete a constantly toxic environment.

And finally, social and community context.

People who lack social support consistently have worse health outcomes.

You need to leverage community support, whether that's school nurses, community health workers, or local support groups, to help manage the chronic condition.

Because at the end of the day, clinical guidelines are vital, but they are just the opening bid.

That is the core takeaway of Chapter 6.

The absolute necessity of individualized therapy cannot be overstated.

You must synthesize the pathophysiology, the genetics, the drugs mechanisms, and the patient's lived reality to write a safe, effective prescription.

The cookie cutter is broken, and honestly, for the sake of patient safety, it needed to be broken.

But this raises an important, almost sci -fi question.

As we discover more and more about specific alleles, exact receptor dynamics, and these complex social variables,

will future pharmacology eventually eliminate standard dosing charts entirely?

Oh, that's interesting.

Like, will we see a day where they are replaced by completely bespoke algorithm -generated prescriptions mathematically tailored to the exact biology of every single patient?

With the rapid advancement of pharmacogenomics and AI, it's a horizon that might be much closer than we think.

It's definitely something provocative to mull over as you study.

We want to say a huge thank you for joining us today.

From the entire last -minute lecture team, we are wishing you the absolute best of luck on your exams, your clinical rotations, and your future practice.

Keep diving deep, and we'll see you next time.